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Articles

Hematopoiesis

Role of the clathrin adaptor PICALM in normal hematopoiesis
and polycythemia vera pathophysiology
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ABSTRACT

Clathrin-dependent endocytosis is an essential cellular process shared by all cell types. Despite this, precisely how
endocytosis is regulated in a cell-type-specific manner and how this key pathway functions physiologically or
pathophysiologically remain largely unknown. PICALM, which encodes the clathrin adaptor protein PICALM,
was originally identified as a component of the CALM/AF10 leukemia oncogene. Here we show, by employing a
series of conditional Picalm knockout mice, that PICALM critically regulates transferrin uptake in erythroid cells by
functioning as a cell-type-specific regulator of transferrin receptor endocytosis. While transferrin receptor is essential for the development of all hematopoietic lineages, Picalm was dispensable for myeloid and B-lymphoid development. Furthermore, global Picalm inactivation in adult mice did not cause gross defects in mouse fitness, except
for anemia and a coat color change. Freeze-etch electron microscopy of primary erythroblasts and live-cell imaging
of murine embryonic fibroblasts revealed that Picalm function is required for efficient clathrin coat maturation. We
showed that the PICALM PIP2 binding domain is necessary for transferrin receptor endocytosis in erythroblasts
and absolutely essential for erythroid development from mouse hematopoietic stem/progenitor cells in an erythroid culture system. We further showed that Picalm deletion entirely abrogated the disease phenotype in a
Jak2V617F knock-in murine model of polycythemia vera. Our findings provide new insights into the regulation of
cell-type-specific transferrin receptor endocytosis in vivo. They also suggest a new strategy to block cellular uptake
of transferrin-bound iron, with therapeutic potential for disorders characterized by inappropriate red blood cell
production, such as polycythemia vera.

Introduction
Erythroblasts take up transferrin-bound iron through the
transferrin receptor (TfR) via clathrin-mediated receptor
endocytosis.1-3 Hemoglobin synthesis by red blood cells
requires a large amount of iron,4 so TfR endocytosis must be
efficiently regulated. However, the factors promoting efficient TfR endocytosis in erythroblasts remain unclear. Such
knowledge is key to our understanding of the pathogenesis of
hematologic disorders, such as iron overload, anemia of
chronic disease and hematologic malignancies.
PICALM, encoded by the phosphatidylinositol binding clathrin
assembly (PICALM) gene, is a clathrin adaptor protein containing multiple domains functioning in clathrin-coated vesicle
formation.5-7 The PICALM gene, also known as CALM
(clathrin assembly lymphoid myeloid leukemia), was originally
identified as a component of the CALM/AF10 leukemia oncogene.8 Genome-wide association studies have recently
demonstrated that single nucleotide polymorphisms in

PICALM are strongly associated with the pathogenesis of
Alzheimer disease.9 Despite extensive efforts to understand
its function, a precise role for PICALM in clathrin-mediated
endocytosis remains largely unknown.
To determine the role of Picalm function in adult
hematopoiesis precisely, we have generated a conditional
knockout mouse strain in which Picalm can be deleted in a
time- and tissue-specific manner. Here we show that
PICALM is critical for clathrin-mediated TfR endocytosis in
erythroblasts; however, it was dispensable for myeloid and Blymphoid development. We further show that Picalm deletion
abrogated the disease phenotype in a Jak2V617F knock-in
murine model of polycythemia vera (PV).

Methods
The gene-targeting strategy for Picalm mutant strains is illustrated in
Online Supplementary Figure S1B. Standard methodology was used to

©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.119537
The online version of this article has a Supplementary Appendix.
Manuscript received on October 22, 2014. Manuscript accepted on December 18, 2014.
Correspondence: tmaeda@partners.org
haematologica | 2015; 100(4)

439

Y. Ishikawa et al.

obtain targeted mutation of Picalm in non-agouti black Bruce4
C57BL/6-Thy1.1 mouse embryonic stem cells.

Results
Picalm-deficient embryos exhibit anemia
and late-stage embryonic lethality
Primary mouse hematopoietic cells from bone marrow
and spleen were sorted by fluorescence activated cell sorting (FACS) and analyzed by western blotting. Picalm protein was predominantly expressed in erythroblasts (Figure
1A). Picalm expression was also abundant in other nonhematopoietic tissues, while Ap180, a Picalm homolog,
was expressed predominantly in brain tissue (Online
Supplementary Figure S1A). Unique isoforms of Picalm protein were evident in muscle and brain (Online
Supplementary Figure S1A). As observed in mouse cells,
PICALM protein was induced in human erythroid cells
when CD34+ hematopoietic stem/progenitors were
induced into an erythroid lineage (Online Supplementary
Figure S1B).10
We next undertook gene targeting to generate mice carrying either one copy of the knockout allele (Picalm+/-) or a
floxed allele (PicalmF/+) (Online Supplementary Figure S1C). In
Picalm-/- embryos, no Picalm protein was detected by western blot using antibodies raised against either the Picalm
N- or C-terminal, confirming successful Picalm deletion
(Online Supplementary Figure S1D and data not shown).
Picalm-/- mice were not viable, dying at late embryonic
stages (Online Supplementary Figure S1E), although the
cause of this in utero death is unclear. Picalm-/- embryos
were smaller and paler than wild-type (WT) and heterozygous littermates (Online Supplementary Figure S1F). At late
embryonic stages, immunohistochemical analysis indicated high cytoplasmic expression of Picalm protein which
was distributed in a punctate pattern within cells of WT
fetal liver, where definitive hematopoiesis occurs (Figure
1B).
Stages of erythroid development in fetal liver can be
characterized by FACS based on expression of TER119
and TfR (CD71) (Figure 1C).11 In Picalm-/- fetal liver cells,
the proportion of R4, a more mature population consisting
mainly of poly/ortho-chromatophilic erythroblasts, was
significantly decreased, while that of R2, an immature
population, increased, suggesting that Picalm is required
for terminal erythroid differentiation (Figure 1D). In agreement, at 14.5 d.p.c. total fetal liver cell counts were significantly lower in Picalm-/- embryos (Figure 1E). Of note, enucleation, revealed by Hoechst stain,12 took place normally
in Picalm-deficient erythroblasts (Online Supplementary
Figure S1G). Picalm heterozygotes (Picalm+/-) were grossly
normal and viable, exhibiting a very mild microcytic anemia (Online Supplementary Figure S1H).

Iron-deficient anemia in hematopoietic-specific
Picalm conditional knockout mice
We generated hematopoietic-specific Picalm knockout
mice (PicalmF/F Mx1Cre+) to assess Picalm function in adult
hematopoiesis. In this model, Cre recombinase is induced
effectively in hematopoietic stem cells by polyinosinicpolycytidylic acid (pIpC) treatment.13 Polymerase chain
reaction genotyping and western blotting confirmed efficient Picalm deletion in hematopoietic cells (Online
Supplementary Figure S2A and data not shown). Peripheral
440

blood counts were analyzed for up to 1 year after pIpC
injection. Picalm-deficient mice were anemic, as evidenced
by significant reductions in red blood cell numbers, hemoglobin and hematocrit (Figure 1F). The anemia was microcytic and hypochromic, as the mean corpuscular volume,
average red blood cell volume, and mean corpuscular
hemoglobin were markedly low (Figure 1G). Benzidine
staining of peripheral blood also suggested reduced intracellular hemoglobin levels and variability in red blood cell
size (Figure 1H). Reticulocyte counts were elevated (Figure
1I) and red cell distribution width, an indicator of variability in red blood cell size and a value typically high in irondeficient anemia, was significantly high in peripheral
blood of Picalm knockout mice (Figure 1J). Variations in cell
size and shape were also evidenced by Wright-Giemsa
staining of peripheral blood smears (Online Supplementary
Figure S2B). Picalm-deficient reticulocytes had a low hemoglobin content and a maturation defect, as indicated by
reduced reticulocyte hemoglobin content and an increase
of percentage immature reticulocyte fraction (%IRF)
(Online Supplementary Figure S2C). Despite the iron-deficiency seen in red cells, serum iron levels were elevated in
PicalmF/F Mx1Cre+ mice (Figure 1K), suggesting that iron
uptake pathways and/or the hemoglobinization process
are impaired in Picalm-deficient erythroid cells. In contrast
to the situation in clinically prevalent iron-deficiency anemia, total iron binding capacity was unchanged and transferrin saturation was slightly elevated (Figure 1L). PicalmF/F
Mx1Cre+ mice did not have a short life span, despite anemia, and tolerated phenylhydrazine-induced hemolytic
stress (Online Supplementary Figure S2D). As expected,
Picalm-deficient megakaryocyte/erythroid progenitors
gave rise to fewer colonies in colony-forming assays, and
individual colonies were smaller than those of controls
(Online Supplementary Figure S2E and data not shown).
Although the difference was not statistically significant,
platelet counts were slightly high in PicalmF/F Mx1Cre+ mice
(Figure 1M).

Picalm is dispensable for myeloid and B-lymphoid
development
To determine whether Picalm is required for the development of all hematopoietic cells, as is TfR,14 we examined myeloid and lymphoid cell counts over time in
peripheral blood upon Picalm deletion. Total white blood
cell counts were comparable to those in controls (Figure
2A), while T-cell counts were slightly low in PicalmF/F
Mx1Cre+ mice (Figure 2A). T-cell development in the thymus was grossly normal (Figure 2B) and development of
non-erythroid cells in the bone marrow was unaffected in
PicalmF/F Mx1Cre+ mice, while the proportion of R4 was
significantly decreased (Figure 2C). Furthermore,
stem/progenitor populations in the bone marrow were
unaffected in PicalmF/F Mx1Cre+ mice (Figure 2D). In agreement with the findings in PicalmF/F Mx1Cre+ mice, B-cellspecific Picalm knockout mice (PicalmF/F mb1Cre+) exhibited
normal B-cell development in the steady state (Online
Supplementary Figure S3A,B). Furthermore, germinal center
B cells developed normally upon immunization with Tcell-dependent antigen (Online Supplementary Figure S3C),
indicating that Picalm is dispensable for B-cell development.
To determine whether observed phenotypes in PicalmF/F
Mx1Cre+ mice are caused by cell-autonomous mechanisms, we performed a bone marrow reconstitution assay
haematologica | 2015; 100(4)
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Figure 1. Picalm knockout mice develop microcytic and hypochromic anemia. (A) Picalm is predominantly expressed in erythroid cells. Mouse
hematopoietic cells from bone marrow (BM), spleen or thymus were FACS-sorted using lineage-specific surface markers. Picalm protein levels
were analyzed by western blot using anti-Picalm antibody. (B) Immunohistochemical analysis for Picalm was performed on formalin-fixed, paraffin-embedded fetal liver (FL) sections of 13.5 d.p.c. embryos. Brown stains in WT FL represent Picalm protein. Complete absence of Picalm protein
in Picalm-/- FL confirmed successful Picalm deletion in vivo. Insets: high magnification images. (C) Erythroid development in FL was analyzed by FACS
based on surface expression levels of TER119 and CD71 (TfR). Each gate (R1 to R5) was determined as described.11 Representative FACS profiles of
Picalm+/+ or Picalm-/- FL cells from 14.5 d.p.c. embryos are shown. (D) Dot graph shows proportions of R4 erythroblasts (TER119+CD71dim+), which consist mainly of ortho-chromatophilic erythroblasts and reticulocytes. Horizontal black bars: average value; error bars: standard deviation. (E) Absolute
counts of 14.5 d.p.c. FL cells, which consist mainly of erythroid lineage cells. Horizontal black bars: average value; error bars: standard deviation. (F)
Time-course analysis of peripheral blood (PB) upon pIpC injection. Three pIpC doses (250 mg/injection) were administered intraperitoneally as
described elsewhere51. PB counts were examined at indicated time points after injections. PicalmF/F Mx1Cre+ mice, but not PicalmF/+ Mx1Cre+ or control mice (PicalmF/+ or PicalmF/F), exhibited a marked reduction in red blood cell counts, hemoglobin and hematocrit. Each plot represents average
values of 10-18 mice; error bars: standard deviation. (G) Dot graphs represent average red blood cell size and average amount of hemoglobin per
red blood cell 3 months after pIpC injections. Error bars: standard deviation. (H) PB smears stained with benzidine, which stains hemoglobin.
Benzidine-negative/dim red blood cells, which contain low concentrations of intracellular hemoglobin, are evident in PB smears of PicalmF/F Mx1Cre+
mice. Sizes and shape of Picalm-deficient red blood cells are more variable than those of control samples. (I) Proportions (left) and absolute counts
(right) of reticulocytes 3 months after pIpC injections. Horizontal black bars: average value; error bars: standard deviation. (J) Red cell distribution
width (RDW), a measure of deviation in red blood cell volume in PB, was markedly increased in PicalmF/F Mx1Cre+ mice. RDW was measured 3
months after pIpC injections. Horizontal black bars: average value; error bars: standard deviation. (K) Levels of iron (Fe), ferritin and transferrin in
serum were measured 2 months after pIpC injections. Serum Fe levels in PicalmF/F Mx1Cre+ mice were higher than those of controls, while ferritin
and transferrin levels were comparable to those in controls. Horizontal black bars: average value; error bars: standard deviation. (L) Total iron binding
capacity (TIBC) and transferrin saturation (%). Horizontal black bars: average value; error bars: standard deviation. (M) Platelets counts 3 months
after pIpC injections. Horizontal black bars: average value; error bars: standard deviation.
haematologica | 2015; 100(4)

441

Y. Ishikawa et al.

A

B

C

D

E

F

Figure 2. Picalm is dispensable for myeloid and B-lymphoid development. (A) Time-course analysis of non-erythroid cells in peripheral blood upon
pIpC injection. White blood cell counts were examined at indicated time points after injections. Proportions of myeloid and lymphoid cells were
determined by FACS. Each plot represents average value of 10-18 mice; error bars: standard deviation. (B) Graph shows frequencies of CD4/8 double-negative (DN), CD4/8 double-positive (DP), CD4 single-positive (CD4SP) and CD8 single-positive (CD8SP) T cells 2 months after pIpC injections
(left). Frequencies of DN fractions (DN1: CD44+CD25-, DN2: CD44+CD25+, DN3: CD44-CD25+ and DN4: CD44-CD25-) are also shown (right). (C)
Representative FACS profiles of bone marrow cells from control (PicalmF/F) and Picalm knockout mice (PicalmF/F Mx1Cre+) 2 months after pIpC injections. (D) Dot graphs of absolute counts (per leg) of hematopoietic stem/progenitors in bone marrow 2 months after pIpC injections. Stem/progenitors were identified by FACS as described elsewhere52. LSK (lineage-Sca1+c-Kit+); HSC (hematopoietic stem cells); MPP (multi-potential progenitors); MkP (megakaryocyte progenitors); GMP: granulocyte macrophage progenitors; PreMegE (pre-megakaryocyte–erythrocyte progenitors).
Horizontal black bars: average value; error bars: standard deviation. (E) Schematic representation of a bone marrow transplant experiment. One
million bone marrow mononuclear cells (BMMNC) from either control (PicalmF/F) or knockout (PicalmF/F Mx1Cre+) mice were transferred to a lethally-irradiated (9 Gy, single dose) recipient mouse along with CD45.1+ 2 x 105 BMMNC (competitors). Recipients were injected with pIpC 1 month
after transplantation (250 mg x 3). (F) Peripheral blood counts were analyzed by a hematology analyzer and FACS 1, 3 and 12 months after pIpC
injections. Each dot represents the average value of 12 samples in each group; error bars: standard deviation.
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(Figure 2E). Recipients of bone marrow reconstituted with
PicalmF/F Mx1Cre+ cells developed anemia after pIpC
administration (Figure 2F), indicating that the anemia seen
in PicalmF/F Mx1Cre+ mice was caused by cell-intrinsic
mechanisms. While Picalm-deficient myeloid and B-lymphoid cells comprised 80-100% of donor-derived cells,
Picalm-deficient T cells exhibited a competitive disadvantage with respect to competitor-derived cells, suggesting
that the T-lymphopenia observed in PicalmF/F Mx1Cre+ mice
also occurred cell-autonomously (Figure 2F).

Transferrin receptor endocytosis is significantly
attenuated in Picalm-deficient erythroblasts
The extent of erythroid differentiation in the spleen can
be characterized by FACS based on cell size (forward scatter: FSC) and levels of expression of TER119, CD71 and
CD44.15,16 A relative increase in the number of immature
erythroblasts (R2) and a concomitant decrease in the number of mature erythroblasts (R4) were evident in spleens of
PicalmF/F Mx1Cre+ mice (Figure 3A,B). PicalmF/F Mx1Cre+
mice also showed a markedly impaired transition from
stage III (consisting mainly of poly-chromatophilic erythroblasts) to stage IV (consisting of ortho-chromatophilic

erythroblasts and reticulocytes) (Figure 3B). Stage II and III
cells, which were predominantly benzidine-positive in
WT erythroblasts, were mostly benzidine-negative in
PicalmF/F Mx1Cre+ mice (Figure 3C), suggesting that irondeficiency caused by Picalm depletion precludes differentiation from poly- to ortho-chromatophilic erythroblasts.
We also found that reduced numbers of mature erythroblasts in Picalm knockout mice were due, at least in part,
to increased apoptosis of erythroblasts (Figure 3D). Serum
erythropoietin levels were significantly high (Figure 3E)
and the spleen was enlarged in PicalmF/F Mx1Cre+ mice
(Figure 3F).
To assess the efficiency of transferrin/TfR endocytosis
in a quantitative manner, we established a FACS-based
TfR endocytosis assay (Figure 4A). Amounts of surfacebound transferrin markedly increased in Picalm-deficient
erythroblasts, particularly those of basophilic and polychromatophilic erythroblasts (Figure 4B). Mean fluorescence intensity of internalized transferrin was significantly
higher relative to that of surface-bound transferrin in WT
erythroblasts; however, it was not in Picalm-deficient cells
(Figure 4B). Transferrin/TfR endocytosis was nearly 25%
as efficient in Picalm-deficient compared to WT erythrob-
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Figure 3. Inefficient erythroid development in PicalmF/F Mx1Cre+ mice. (A) Representative FACS profiles of splenic erythroblasts from control
(PicalmF/F) and Picalm knockout mice (PicalmF/F Mx1Cre+) 2 months after pIpC injections. Immature erythroblasts (R2) did not efficiently give rise
to mature erythrocytes (R4). (B) Bar graphs show proportions of R4 erythroblasts in the spleen 1 month after pIpC injections (left). Proportions of
CD44/FSC-based sub-fractions16 are also shown (right). Histograms: average value of three samples per genotype; error bars: standard deviation.
(C) Benzidine staining of splenic erythroblasts. FACS-sorted erythroblasts were cyto-spun onto glass slides and stained with benzidine, an indicator
of intracellular hemoglobin levels. Graph shows frequencies of benzidine-positive cells in stage II and III cells.16 Almost all cells at stage III were
benzidine-positive in control cells, while only 20% of Picalm-deficient erythroblasts stained positive. Histograms: average value of three samples
per genotype; error bars: standard deviation. (D) Apoptosis of R2 erythroblasts was measured by FACS by appearance of cleaved PARP (left) and
annexin V-staining (right) 2 months after pIpC injections. Histograms: average value of four samples per genotype; error bars: standard deviation.
(E) Dot graph shows serum erythropoietin levels 2 months after pIpC injections. In response to hypoxia in the periphery, erythropoietin levels in
Picalm knockout mice were 20-fold higher than those seen in controls. Horizontal black bars: average value; error bars: standard deviation. (F) Dot
graphs represent average spleen weight 2 months after pIpC injections (left). Horizontal black bars: average value; error bars: standard deviation.
Representative picture of spleens (right).
haematologica | 2015; 100(4)
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lasts (Figure 4C). Total TfR protein levels in Picalm-deficient erythroblasts were comparable to those in control
cells (Figure 4D), suggesting that TfR endocytosis, but not
its expression, is regulated by Picalm. Of note, regardless
of high TfR expression, Picalm was barely detected in
bone marrow macrophages (Figure 4D). Importantly,
amounts of surface-bound and internalized Alexa647transferrin were unchanged in B-lymphoid and myeloid
cells regardless of the genotype (Online Supplementary
Figure S3D).

Picalm is necessary for clathrin-coat maturation
To further understand the role of Picalm in clathrin-coated vesicle formation in erythroblasts, we performed
freeze-etch electron microscopy.17 The representative
images indicated a decrease in the number of fully-formed
clathrin coated pits in Picalm-deficient erythroblasts when
compared to images from WT cells (Figure 5A and Online
Supplementary Figure S4A). Clathrin-mediated TfR endocytosis is a dynamic process consisting of multiple steps

(Figure 5B).18 We established immortalized mouse embryonic fibroblasts (MEF) in which Picalm can be deleted in an
inducible manner (PicalmF/F ERT2-Cre+ MEF) (Figure 5C).
We then stably transduced these MEF with retrovirus
encoding an EGFP-tagged adaptin σ2 (σ2-EGFP) that efficiently co-assembled with the endocytic clathrin adaptor
AP2 complex to image dynamic processes of clathrin-coated pit formation.19,20 As Picalm was almost completely
depleted by 48 h after tamoxifen treatment (Figure 5C),
we carried out our experiments using MEF treated with
vehicle or tamoxifen for 72 h.
We first performed electron microscopy in MEF upon
induction of Picalm deletion. We observed a substantial
increase in the shallow pit fraction and a decrease in the
fraction of mature vesicles in PicalmF/F ERT2-Cre+ MEF
upon tamoxifen treatment (Figure 5D). We then used live
cell spinning-disk confocal fluorescence microscopy to
characterize the consequences of depleting Picalm in the
formation dynamics of AP2-containing endocytic clathrincoated structures. Assembly of the clathrin/AP2 coats at
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Figure 4. TfR endocytosis is impaired in Picalm-deficient erythroblasts. (A) FACS-based transferrin/TfR endocytosis assay. To measure the amount
of internalized transferrin, splenocytes were incubated at 37°C for 8 min with Alexa-647 transferrin, chilled to 4°C (to stop endocytosis) and
washed with low-pH buffer to remove transferrin bound to the cell surface. For surface-bound transferrin, cells were incubated at 4°C with Alexa647 transferrin and then washed with neutral pH buffer. Samples were then incubated with fluorescently-tagged antibodies specific for erythroid
and lymphoid cells and subjected to FACS analysis. As a background control, splenocytes were incubated with at 4°C with Alexa-647 transferrin
for 8 min, washed with acid buffer and analyzed by FACS. Efficiency of transferrin (Tf) endocytosis was calculated by dividing mean fluorescence
intensity (MFI) of internalized transferrin by that of surface-bound transferrin. (B) Representative FACS profiles of transferrin/TfR endocytosis assay
in erythroblasts. MFI of internalized- (blue lines) and surface bound- (red lines) transferrin was measured by FACS at different stages of erythroid
differentiation. Background signals are also presented for each population (green lines). Red-dashed lines indicate levels of surface-bound Alexatransferrin in control erythroblasts. (C) Bar graphs show efficiencies of transferrin endocytosis in basophilic and polychromatophilic erythroblasts.
Experiments were repeated three times, and representative results are presented. Histograms: average value of two samples per genotype; error
bars: standard deviation. (D) Western blot for TfR in FACS-sorted erythroblasts. Samples from two mice per genotype (control: #1 and #2, Picalm
knockout: #3 and #4) were analyzed. TfR protein levels in Picalm-deficient erythroblasts were comparable to those of controls. Western blot for
H-ferritin, indicative of intracellular iron storage; Picalm and Tubulin are also shown. Mφ: protein lysates of bone marrow macrophages. Asterisk:
non-specific signal.
444

haematologica | 2015; 100(4)

Cell-type-specific regulation of TfR endocytosis

A

B

C

D

E

F

G

H

Figure 5. Formation of clathrin-coated vesicles in Picalm-deficient cells. (A) Representative pictures of freeze-etch electron microscopy in primary
splenic erythroblasts. Formation of mature vesicles was barely observed in Picalm-deficient erythroblasts. Arrows indicate clathrin-coated vesicles. (B)
Formation of endocytic clathrin-coated structures on the plasma membrane. The process of clathrin-dependent endocytosis is dynamic and has multiple steps, including initiation, maturation, scission and uncoating. (C) Generation of mouse embryonic fibroblasts (MEF) in which Picalm is inducibly
deleted by tamoxifen treatment (PicalmF/F ERT2-Cre+ MEF). MEF were established from a 13.5 d.p.c PicalmF/F ERT2-Cre+ embryo, immortalized with large
T antigen and retrovirally transduced with EGFP-tagged AP2-bound adaptin σ2 (σ2-EGFP).19,20 Western blot for Picalm confirmed inducible depletion of
Picalm protein in tamoxifen-treated but not control DMSO-treated MEF (right). Two splice forms of Picalm (Picalm-long and -short) were evident in MEF,
and both were absent after tamoxifen treatment. (D) Relative frequency of each clathrin structure was measured 72 h after tamoxifen (or DMSO) treatment of PicalmF/F ERT2-Cre MEF. The proportion of mature vesicles was significantly reduced in tamoxifen-treated (Picalm-deleted) MEF. (E) Summary
of the various cell types used to acquire live-cell imaging data using spinning-disk confocal microscopy of PicalmF/F ERT2-Cre+ MEF cells stably expressing AP2 (σ2-EGFP). Picalm KO denotes Picalm deletion by tamoxifen addition; Ap180 KD denotes Ap180 knockdown by shRNA. The general statistics
indicate the number of cells analyzed per condition as well as the average ± SD of coated pits (events) per cell and the total number of events detected
using the tracking algorithm described by Aguet et al.21 Coated pits are structures that gained fluorescence intensity relative to the first detected time
point. The plot shows the lifetime distributions for coated pits. (F) Plots corresponding to the average fluorescence intensities from the corresponding
number of cells, calculated from productive coated pit trajectories binned by lifetime represented as mean intensity (solid lines) and standard error
(shaded areas). The top of each graph indicates the average percentage of coated pits within each cohort. (G) The panel corresponds to the area density
of coated pits that formed per min during the 5 min duration of the time-series. (H) The panel shows the density of persistent structures, defined as
structures present for the full duration of the time-series. Box plots show median, 25th, and 75th percentiles, and outermost data points. Statistical significance was determined using the permutation test for medians.
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the surface of the MEF attached to the glass coverslip was
followed using an automated unbiased tracking
approach.21 Whereas loss of Picalm or Ap180 alone had no
noticeable effects on coat dynamics, simultaneous deletion of Picalm (knockout) and short hairpin RNA-mediated
knock-down of Ap180 (Online Supplementary Figure S4B,C)
led to a significant increase in the lifetime of the coated
pits/vesicles (Figure 5E,F) together with a substantial
decrease in the number of coated pits (Figure 5G); the
number of long-lasting structures (plaques) was only
slightly affected (Figure 5H).

The Picalm PIP2 binding domain is essential
for transferrin receptor endocytosis
Picalm binds to r-soluble NSF attachment protein receptors (r-SNARE) and to the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) through its N-terminal ANTH (AP180 N-terminal homology) domain and
interacts with clathrin as well as other accessory proteins
(Figure 6A).5-7,22 Of note, Picalm normally exists as two
splice isoforms that differ by inclusion or exclusion of
exon 13, which encodes 51 amino acids exhibiting a DPF
and an NPF motif (Figure 6A).
To determine amino acid residues/domains required for
Picalm function in erythroblasts, we performed add-on
rescue experiments using a series of Picalm mutants
(Figure 6A and Online Supplementary Figure S4D). To do so,
we established K562 erythro-leukemia cells stably
expressing short hairpin RNA targeting PICALM and then
“added-back” each PICALM mutant via retroviral transduction, followed by FACS-based transferrin endocytosis
assays. Among mutants tested, PIP2-PICALM, which cannot bind PIP2 due to replacement of three lysine residues
(38KKK40) with glutamic acid (38EEE40) (Online
Supplementary Figure S4D),6 failed to rescue transferrin
uptake in PICALM-knockdown K562 cells (Figure 6C,D),
indicating that PIP2 binding is necessary for PICALMmediated TfR endocytosis. Expression levels of PIP2PICALM protein was comparable to that of WT-PICALM,
confirmed by western blotting (Online Supplementary
Figure S4E). Addback of Picalm mutants unable to interact
with the r-SNARE VAMP 2, 3 and 8, fully rescued the
uptake of transferrin, suggesting that traffic of these rSNARE is not required for efficient transferrin uptake.
Similar results were obtained with the add-back of Picalm
mutants unable to interact with either clathrin or AP2. In
this case, maintaining either one of these interactions was
sufficient to sustain efficient transferrin uptake.

Picalm/PIP2 interaction is necessary for erythroid
differentiation
To determine the function of PICALM/PIP2 interaction
in erythroid development, we employed a culture system
that recapitulated erythroid differentiation from progenitors in vitro.11,23 WT- and Picalm-deficient bone marrow cells
were depleted of mature lineage marker-positive cells
(erythroid, myeloid and lymphoid cells) in order to enrich
the hematopoietic progenitors, and progenitors were then
cultured in the presence of erythropoietin, holo-transferrin
and insulin for 3 days (Online Supplementary Figure S5A).23
Progenitors from control mice (PicalmF/F) differentiated into
mature erythroblasts after 3 days of culture, as previously
described (Figure 6E,F).11,23 In contrast, Picalm-deficient progenitors barely developed into an erythroid lineage (Figure
6E,F), and most cells remaining on day 3 were CD11b+
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myeloid cells. Wright-Giemsa staining of cytospin preparations showed enrichment of erythrocytes and erythroblasts in WT cells, while Picalm-deficient cells mainly consisted of myeloid lineage cells (segmented neutrophils,
banded
neutrophils
and
myeloblasts)
(Online
Supplementary Figure S5B). Ferric ammonium citrate incorporates into cells through “TfR-independent” mechanisms.24 Importantly, treatment with ferric ammonium citrate dose-dependently restored development of Picalmdeficient mature erythroblasts (Figure 6G), indicating that
lack of TfR-mediated iron uptake is the primary cause of
erythroid defects seen in Picalm-deficient cells in vitro.
We next examined whether exogenous expression of
WT- or PIP2-PICALM would rescue erythroid differentiation in Picalm-deficient progenitors. To do so, we harvested bone marrow progenitor cells from PicalmF/F Mx1Cre+
mice 1 month after pIpC injection, retrovirally transduced
them with either WT- or PIP2-PICALM and then induced
erythroid differentiation (Figure 6H). Since the retrovirus
also encodes a green fluorescent protein, we assessed the
extent of erythroid differentiation in the fraction positive
for this protein. As expected, WT-PICALM completely
rescued erythroid differentiation in Picalm-deficient cells,
while PIP2-PICALM-transduced cells barely differentiated
into mature cells (Figure 6I,J). We also tested a PICALM
mutant in which the ANTH domain was replaced with
the PH domain of rat phosphlipase C delta 1 (PHPICALM), a motif that harbors a lipid-binding domain
specific to PIP2.25 PH-PICALM failed to rescue erythroid
differentiation in Picalm-deficient cells, indicating that
PICALM binding to PIP2 is necessary but not sufficient for
erythroid differentiation.

Picalm inactivation ameliorates the pathophysiology
of polycythemia vera in mice
Although Picalm was abundant in non-hematopoietic
tissues (Online Supplementary Figure S1A), global Picalm
inactivation in adult mice (PicalmF/F ERT2-Cre+) did not
cause gross defects in mouse fitness, except for anemia
and a coat color change (Online Supplementary Figure S6).
Upon intraperitoneal injections of tamoxifen, Picalm inactivation was achieved in all tissues examined except the
brain (Online Supplementary Figure S6A). PicalmF/F ERT2-Cre+
mice exhibited a microcytic and hypochromic anemia and
inefficient erythroid differentiation in the spleen, as did
PicalmF/F Mx1-Cre+ mice (Online Supplementary Figure
S6B,C). Picalm deficiency did not affect postnatal development and the body weights of PicalmF/F ERT2-Cre+ mice
were comparable to those of control mice (Online
Supplementary Figure S6D and data not shown). Coat-color
graying was observed upon Picalm inactivation, suggesting
that Picalm functions in melanin synthesis and/or
melanosome transfer (Online Supplementary Figure S6E).
Considering that Picalm deletion limits terminal erythroid
differentiation through the induction of iron depletion in
erythroblasts and that Picalm is likely dispensable in nonhematopoietic tissues in adult animals, we sought to
explore the impact of Picalm deletion in a disease characterized by an excess production of mature red blood cells,
namely polycythemia vera (PV).
In PV, erythroid precursor cells aberrantly expand as a
result of enhanced signaling downstream of the erythropoietin receptor due to an activating mutation in JAK2 kinase
(JAK2V617F). We crossed Picalm conditional knockout mice
with a conditional knock-in Jak2V617F mouse model of PV
haematologica | 2015; 100(4)
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Figure 6. PICALM/PIP2 interaction is critical for erythroid differentiation. (A) Structure of human PICALM protein and predicted domains/motifs. Exon
13 is spliced out in the PICALM short form. Every mutant defined at the top was tested for its capacity to rescue PICALM deficiency. Mutated residues
in each mutant are described in Online Supplementary Figure S4D. (B) Experimental outline of “add-back” rescue experiments using PICALM-knockdown K562 leukemia cells (left). Lentivirus vectors encoding shRNA targeting the PICALM 3’UTR were generated, and knockdown efficiency in K562
leukemia cells was tested by western blot. K562 cells stably expressing PICALM shRNA#1 were used for the experiment (right). Each PICALM mutant
was retrovirally “added-back” into PICALM-knockdown K562 cells and transferrin uptake analyzed 4 days after transduction. Retrovirus also encodes
a mCherry fluorescent protein, allowing tracking of cells expressing mutant or WT PICALM. (C) FACS-based transferrin/TfR endocytosis assays were
performed as described. Representative FACS profiles of empty vector-, WT-PICALM (long form)- and PIP2-PICALM- infected cells are shown. (D)
Efficiency of transferrin endocytosis in mCherry-positive cells was calculated as described in Figure 4A. Histograms show the relative efficiency of transferrin endocytosis upon “add-back” of empty vector or PICALM mutants. Transferrin endocytosis was significantly reduced in empty- or PIP2-PICALMtransduced cells compared to that of WT-PICALM-transduced cells. In contrast, other PICALM mutants enhanced TfR endocytosis in PICALM-knockdown K562 cells up to levels seen with WT-PICALM. Histograms: average value of two to four samples per condition; error bars: standard deviation.
(E) Erythroid development in culture was examined daily for 3 days after induction of erythroid differentiation. Representative FACS profiles of controland Picalm-deficient cells are shown. The extent of erythroid differentiation was assessed by FACS based on surface marker expression levels (TER119
and CD71) and cell size [forward scatter (FSC) and side scatter (SSC)]. R4 cells (TER119+CD71dim+), which consist mainly of ortho-chromatophilic erythroblasts and reticulocytes, are depicted with red rectangles. Fully-differentiated erythroid cells are smaller than immature erythroblasts and fall into
the FSClow SSClow fraction. (F) Bar graphs show frequencies of mature erythroblasts after 3 days of culture. Picalm-deficient stem/progenitors gave rise
to markedly fewer mature erythroblasts compared to controls. Experiments were repeated at least four times, and representative results are presented. Histograms: average value of two samples per genotype; error bars: standard deviation. (G) Iron supplement treatment (ferric ammonium citrate:
FAC) significantly enhanced erythroid development of Picalm-deficient progenitors in a dose-dependent manner. Bar graphs show cell counts of each
fraction (R0-R4) on day 2 in the presence or absence of FAC in the culture medium. Experiments were repeated three times, and representative results
are presented. (H) Functional rescue experiments. Bone marrow stem/progenitor cells were obtained from PicalmF/F Mx1Cre+ mice 2 months after pIpC
injections and transduced with retrovirus vectors encoding WT- or PIP2-PICALM. Transduced cells were subsequently induced for erythroid differentiation as described. The extent of erythroid differentiation was examined by FACS within GFP-positive (transduced) fractions. (I) Representative FACS profiles of WT- or PIP2-PICALM-transduced cells after 3 days of culture. FACS profiles for GFP-positive fractions are shown. WT-PICALM fully rescued Picalm
deficiency in erythroid development: greater than 40% of GFP-positive (WT-PICALM-transduced) cells were mature erythroblasts on day 3, while PIP2PICALM (or PH-PICALM)-transduced cells were not rescued. (J) Histograms show proportions of mature erythroblasts (%R4 and %FSClow SSClow) in empty
vector-, PIP2- or WT-PICALM-transduced cells after 3 days of culture. Experiments were repeated three times, and representative results are presented.
Histograms: average value of two samples per condition; error bars: standard deviation.
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Figure 7. Picalm deletion ameliorates PV pathophysiology in mice. (A) Hematopoietic-specific Picalm conditional knockout mice were bred with PV
mice (Jak2+/V617FVav-Cre+) to generate Picalm-deficient PV mice (PicalmF/FJak2+/V617FVav-Cre+). Four indicated groups were analyzed. (B) Time-course analysis of peripheral blood. Picalm-deficient PV mice (green line) exhibited a marked reduction in red blood cell counts, hemoglobin and hematocrit compared to PV mice (red line). Graphs represent average values of three of eight mice for each genotype. Error bars: standard deviation. (C) Total RNA
was extracted from PB without red blood cell lysis and cDNA was prepared using standard methodology. Expression of WT and mutant Jak2 (Jak2 V617F)
mRNA was analyzed by reverse transcription polymerase chain reaction (RT-PCR) using allele-specific primers as described.27 Mutant Jak2 transcripts
were detected only in PB samples from PV and Picalm-deficient PV mice. RT-PCR for the housekeeping genes b-actin and Hprt was also performed.
A representative gel is shown. (D) Jak2 kinase activity was examined by western blotting for the phosphorylated form of Stat5 (p-Stat5). Splenic erythroblasts were serum-starved for 2 h, treated with erythropoietin (EPO) for 10 min and protein extracts prepared. Western blot for Jak2 and Stat5 are
also shown. Hsp90: loading control. Splenic erythroblasts of control mice were obtained after phenylhydrazine (PHZ) treatment. (E) mRNA levels of BclXL in splenic erythroblasts were examined by realtime quantitative RT-PCR. (F) Time-course analysis of myeloid and lymphoid cell counts in PB. (G)
Endocytic rate of transferrin/TfR in splenic erythroblasts was measured by FACS as described. (H) The Jak2 V617F mutation causes constitutive activation
of the Jak/Stat pathway in erythroid progenitors, leading to expansion of immature erythroblasts. PV mice exhibit a relative iron deficiency due to erythroid cell overproduction. In Picalm knockout (KO) mice, serum erythropoietin (EPO) levels are high and EPO/EPOR-mediated Jak/Stat signals are
activated in erythroblasts; however, erythropoiesis (mature red cell production) is inefficient as TfR-mediated cellular iron uptake is impaired. In Picalmdeficient PV mice, regardless of Jak2 V617F-driven Jak2/Stat5 activation, Picalm deficiency limits iron availability in erythroblasts, blocking red cell overproduction.
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(Jak2+/V617F Vav-Cre+).26,27 Hematopoietic-specific Picalm
knockout mice (PicalmF/F Vav-Cre+) are viable and phenocopy
PicalmF/F Mx1Cre+ mice. We established and analyzed four
groups of mice (Figure 7A). Mice with PV had significantly
increased red blood cell counts and hemoglobin levels as
well as elevated hematocrit,26 while PicalmF/F Vav-Cre+ mice
exhibited microcytic anemia (Figure 7B). Despite expression
of mutant Jak2 (Figure 7C), Picalm-deficient PV mice (PV
Picalm knockout) developed microcytic and hypochromic
anemia, as did Picalm knockout mice (Figure 7B).
Importantly, Picalm deficiency did not alter Jak2 kinase
activity (Figure 7D) and mRNA levels of Bcl-XL, a Jak/Stat
target, were unaffected (Figure 7E). Although statistically
insignificant, white blood cell counts, specifically counts of
Gr-1+CD11b+ myeloid cells, appeared low in Picalm-deficient PV mice. T-cell numbers were reduced in Picalm
knockout and Picalm-deficient PV mice, as observed in
PicalmF/F Mx1-Cre+ mice (Figure 7F). Mild thrombocytosis,
which was likely due to secondary effects of severe irondeficiency,28 was observed in Picalm-deficient PV mice
(Figure 7F). As expected, TfR endocytosis was impeded in
erythroblasts of Picalm knockout and Picalm-deficient PV
mice (Figure 7G). Taken together, Picalm deficiency limits
iron uptake in PV erythroblasts, effectively abrogating the
polycythemia phenotype seen in these animals.

Discussion
PICALM binds to PIP2 in the plasma membrane through
its N-terminal ANTH domain and interacts with clathrin
and other accessory proteins to form clathrin cargo, presumably playing a key role in clathrin-coated pit formation.5-7 PICALM loss reportedly decreases uptake of specific r-SNARE associated with endosomal traffic.22 This effect
has been noted in cells maintained in culture; of note,
most tissues in mice lacking Picalm appear normal, suggesting either a very restricted role of Picalm in the intracellular traffic of these r-SNARE or the up-regulation of a
compensatory route. Knockout of AP180, a PICALM
homolog, in flies results in slightly larger synaptic vesicles
than those seen in normal flies;29,30 however, PICALM
depletion by short interfering RNA in cell lines has no
effect on receptor-mediated transferrin uptake and a minimal effect on the morphology of clathrin coats.7,31-33 Our
visualization studies with MEF indicate relatively modest
effects on endocytic coat dynamics attained upon simultaneous depletion of both Ap180 and Picalm whereas no
detectable effects were observed in MEF subjected to
Ap180 or Picalm depletion alone. The increase in lifetime
combined with the decrease in the number of mature
coated pits/vesicles are effects that can account for the
observed decrease of transferrin uptake in erythroblasts.
It has been shown that anemia-promoting mutations at
the Fit1 locus in mice occur in the Picalm gene.34-36 Studies
of Fit1 mutants, although useful, do not represent an ideal
model for understanding the role of PICALM, because
they are heterozygous for a Picalm point mutation and harbor the Del26DVT deletion in the other allele, removing a
11cM segment including the Picalm gene.34-36 Suzuki and
colleagues recently reported a conventional Picalm knockout strain.37 They reported that more than 90% of Picalm-/newborn pups die before weaning and body weights of
surviving Picalm-/- mice are significantly lower than those
of controls.37 Since the surviving Picalm-/- mice had severe
haematologica | 2015; 100(4)

growth retardation and liver damage, it is likely that the
hematopoietic phenotypes of these mice are secondary
effects of the growth retardation and liver dysfunction. In
fact, these phenotypes differ significantly from those of
conditional knockout models. Although severe B-cell
defects have been reported in Picalm-/- mice, none of our
conditional or transplant models exhibited a B-cell phenotype. While we observed significant expansion of immature erythroblasts exhibiting inefficient erythropoiesis
(Figures 2 and 3), Suzuki et al. observed somewhat reduced
numbers of erythroblasts in the bone marrow and spleen.37
Phenotypes observed in Picalm knockout mice differ
from those seen in clinically prevalent iron-deficiency anemia (e.g. the former have high reticulocyte counts and
high serum iron levels). In contrast to the situation in typical iron-deficiency anemia, iron is not “absolutely deficient” in Picalm knockout mice. Transferrin-bound iron is
abundant in the sera of Picalm knockout mice (Figure 1),
and levels of transferrin-bound surface TfR increase in
Picalm-deficient erythroblasts (Figure 4). Thus, Picalm-deficient erythroblasts may take up transferrin-bound iron
through a “clathrin-independent” endocytosis pathway
(e.g. fluid-phase uptake).38 Such a pathway may provide
Picalm-deficient erythroblasts with the minimum amount
of iron required to give rise to reticulocytes under strong
erythropoietic conditions. Alternatively, since the transition from reticulocytes to erythrocytes is accompanied by
extensive structural changes in the plasma membrane and
elimination of organelles,39,40 Picalm deficiency may impair
reticulocyte maturation by modulating these pathways.
TfR-deficient (TfR-/-) embryonic stem cells give rise to
bone marrow B cells in chimeric mice; however, T-cell
development is arrested at the CD4/8 DN stage, suggesting that TfR is indispensable for immature T-cell development in the thymus.14 We found that T-cell development
in the thymus of PicalmF/F Mx1Cre+ mice was grossly normal, and the numbers of CD4- and CD8- T cells in peripheral blood were reduced to the same extent (Figure 2B).
These data suggest that the observed T-cell phenotype is
not due to a block of differentiation at a specific stage of
T-cell development. It is possible that a small fraction of
CD4/8 DN T cells require Picalm-mediated TfR endocytosis, causing a mild T-lymphopenia in PicalmF/F Mx1Cre+
mice.
Erythroid progenitors give rise to red blood cells in culture without the support of other lineage cells.11 In vivo,
however, erythroid progenitors differentiate into red
blood cells in a specialized niche called the erythroblastic
island.41 Several cell adhesion molecules and their interacting partners within erythroblastic islands are reportedly
necessary for island integrity.42,43 Central macrophages supposedly provide nutrients and growth factors, including
iron, to erythroblasts and function to induce erythroid
maturation.41,44,45 TfR knockout mice die in utero due to anemia before embryonic day 12.5; however, TfR-deficient
embryos can produce a substantial amount of red cell
mass as late as 10.5 d.p.c.46 In contrast, yolk sac-derived
TfR-deficient progenitors do not give rise to erythroid
colonies in vitro,46 suggesting that the “TfR-independent”
iron uptake pathway is available only in vivo. We see similar phenotypes in Picalm conditional knockout mice:
Picalm-deficient hematopoietic progenitors do not give rise
to erythroblasts in vitro, while erythroblasts are greatly
expanded in spleen and bone marrow. There are a few
explanations for the observed discrepancies between in
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vivo and in vitro phenotypes. Picalm-deficient erythroid progenitors could take up transferrin-bound iron through a
Picalm-independent pathway in vivo (for example via
direct contact with surrounding cells). Alternatively, nontransferrin-bound iron, potentially available in the local
micro-environment, could supply a minimal amount of
iron for erythroblast survival in vivo.
Iron chelators are widely used in the clinic to prevent
organ damage due to iron overload.47 At the therapeutic
dosage, they target primarily non-transferrin-bound iron,
while transferrin-bound iron remains intact.48 Since highly
proliferating cells depend on metalloenzymes, iron and its
internalization pathways are considered attractive targets
for cancer therapy. Iron chelators have been tested for antitumor activity49 and, as hematologic cancer cells generally
express high surface levels of TfR, multiple TfR antibodies
have been tested as anti-cancer agents over the last 25
years.50 Our findings suggest a novel strategy to target transferrin-bound iron. Picalm deletion causes iron deficiency in
PV erythroblasts leading to reduced red cell mass, and completely abrogates the polycythemia disease phenotype in
mice (Figure 7B). Since global Picalm inactivation did not
cause gross defects in mouse fitness (Online Supplementary
Figure S6), targeting PICALM for hematologic malignancies
might be feasible and warrants attention as a therapeutic
approach. Since PICALM is abundant in a series of cancer
cells, our Picalm conditional strain may be useful to assess
effects of Picalm deletion in mouse cancer models.
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